ScholarGate
Avustaja

Vertaile menetelmiä

Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.

Päätösanalyyttinen mallinnus terveydenhuollon taloustieteessä×Markov-mallin käyttö terveys taloustieteessä×
TieteenalaTerveystaloustiedeTerveystaloustiede
MenetelmäperheProcess / pipelineProcess / pipeline
Syntyvuosi19751983
KehittäjäPauker & Kassirer (medical decision analysis, Massachusetts General Hospital)Beck & Pauker (medical decision analysis, Massachusetts General Hospital)
TyyppiMethodMethod
AlkuperäislähdePauker, S. G., & Kassirer, J. P. (1975). Therapeutic Decision Making: A Cost-Benefit Analysis. New England Journal of Medicine, 293(5), 229-234. DOI ↗Beck, J. R., & Pauker, S. G. (1983). The Markov Process in Medical Prognosis. Medical Decision Making, 3(4), 419-458. DOI ↗
Rinnakkaisnimetdecision analysis, decision tree, decision model, health economic modelMarkov model, state transition model, cohort simulation
Liittyvät55
TiivistelmäDecision analytic modeling is a systematic framework for comparing health interventions by integrating evidence on probabilities, outcomes, costs, and patient preferences into a quantitative model. Developed by Pauker and Kassirer in 1975, decision analysis structures clinical uncertainty and economic trade-offs, enabling transparent comparison of treatment options and identification of optimal strategies. Used in health technology assessment, clinical practice guideline development, and resource allocation decisions.A Markov model is a decision-analytic tool that simulates disease progression through defined health states over time, calculating cumulative costs and quality-adjusted life years (QALYs) to enable cost-effectiveness analysis. Developed by Beck and Pauker in 1983, Markov models are now the standard framework for projecting long-term outcomes of health interventions, especially chronic diseases where patients transition between clinical states (treatment response, disease progression, remission, death). Used by health technology assessment bodies and pharmaceutical companies to predict intervention value beyond trial duration.
ScholarGateAineisto
  1. v1
  2. 3 Lähteet
  3. PUBLISHED
  1. v1
  2. 3 Lähteet
  3. PUBLISHED

Siirry hakuun Lataa diat

ScholarGateVertaile menetelmiä: Decision Analytic Modeling · Markov Model in Health Economics. Haettu 2026-06-20 osoitteesta https://scholargate.app/fi/compare